How to Use This Calculator
This PI-RADS v2.1 calculator computes the assessment category for a single prostate MRI lesion based on zone (PZ or TZ), T2W score, DWI score, and DCE status. Follow these steps:
- Select the lesion zone — Identify whether the lesion is in the Peripheral Zone (PZ) or Transition Zone (TZ). The peripheral zone is the posterior and lateral glandular tissue; the transition zone surrounds the urethra and is the site of benign prostatic hyperplasia (BPH). The dominant scoring sequence differs by zone, so zone selection is required before scoring.
- Score T2-weighted imaging (T2W) — Select the T2W score (1–5) based on the lesion's morphology and signal characteristics in the appropriate zone. T2W criteria differ between PZ and TZ, so the calculator displays zone-specific options after zone selection.
- Score DWI/ADC — Select the DWI score (1–5) based on the degree of diffusion restriction. DWI scores reflect hypointensity on the ADC map and corresponding hyperintensity on high b-value DWI images.
- Record DCE status — Select positive if there is focal early or simultaneous enhancement in the lesion corresponding to the T2W/DWI finding. Select negative if no such enhancement exists. For PZ lesions only, DCE upgrades a score of 3 to PI-RADS 4. For TZ lesions, DCE does not affect the PI-RADS score.
- Review the PI-RADS result — The calculator applies the v2.1 algorithm and displays the final PI-RADS assessment category with biopsy guidance. Review the breakdown panel to verify the input values and confirm the score calculation.
Note: This calculator scores a single lesion. Most prostate MRI studies contain multiple zones and potentially multiple lesions — the radiologist assigns a PI-RADS score to each suspicious lesion individually, and the overall study impression is determined by the highest-scoring lesion. Clinical decisions must integrate PI-RADS score with PSA density, prior biopsy history, patient age, and urological assessment.
About PI-RADS v2.1
The Prostate Imaging Reporting and Data System (PI-RADS) v2.1 is the current standard for reporting prostate multiparametric MRI (mpMRI). Jointly developed by the American College of Radiology (ACR), the European Society of Urogenital Radiology (ESUR), and the AdMeTech Foundation, it provides a structured scoring framework to stratify the likelihood of clinically significant prostate cancer (csPCa), defined as Gleason score ≥7 (grade group ≥2), on a 1–5 ordinal scale. PI-RADS v2.1 was published in 2019 as a refinement of v2 (2015), with targeted changes to reduce interreader variability and improve reproducibility.
Prostate cancer is the most common non-skin cancer in men, with approximately 1 in 8 American men receiving a diagnosis during their lifetime. The clinical challenge is distinguishing clinically significant cancer (which requires treatment) from indolent low-grade disease (Gleason 6 / grade group 1, which rarely metastasizes and may be managed by active surveillance). Historically, transrectal ultrasound-guided systematic (random) biopsy was the standard diagnostic approach, but it misses up to 30–40% of significant cancers located in areas that are difficult to sample systematically (particularly anterior and apical regions) while simultaneously detecting many indolent cancers that would never have caused harm. mpMRI prior to biopsy has transformed prostate cancer diagnosis by providing spatial localization of suspicious lesions, enabling targeted biopsy of the most suspicious areas while reducing detection of clinically insignificant disease.
The PROMIS trial (Ahmed et al., Lancet 2017) demonstrated that mpMRI before biopsy detected 93% of clinically significant cancers (vs. 48% for systematic biopsy alone) and reduced detection of insignificant cancers by 89%. Subsequent trials including PRECISION (Kasivisvanathan et al., NEJM 2018) confirmed that MRI-targeted biopsy was non-inferior to systematic biopsy for detecting clinically significant cancer while significantly reducing detection of insignificant cancer. These landmark studies established mpMRI + PI-RADS as the standard of care pathway for men with suspected prostate cancer, now reflected in guidelines from the American Urological Association (AUA), the European Association of Urology (EAU), and the National Comprehensive Cancer Network (NCCN).
Dominant Sequence by Zone
PI-RADS v2.1 uses different dominant sequences depending on lesion location:
- Peripheral Zone (PZ): DWI is the dominant sequence. T2W and DCE are secondary. A DWI score of 3 combined with positive DCE upgrades to PI-RADS 4. DWI scores of 4 or 5 determine the final PI-RADS score regardless of other sequences.
- Transition Zone (TZ): T2W is the dominant sequence. DWI is secondary. A T2W score of 3 combined with DWI ≥4 upgrades to PI-RADS 4. DCE has no role in TZ scoring under v2.1.
PI-RADS Assessment Categories
| PI-RADS | Description | csPCa Risk | Management |
|---|---|---|---|
| 1 | Very low suspicion | ≈2% | No targeted biopsy |
| 2 | Low suspicion | ≈6% | No targeted biopsy (consider systematic bx) |
| 3 | Intermediate suspicion | ≈16% | Targeted biopsy or active surveillance (PSA density) |
| 4 | High suspicion | ≈35% | Targeted biopsy recommended |
| 5 | Very high suspicion | ≈60–75% | Targeted biopsy recommended |
Interpretation Guide
PI-RADS 1 and 2 — No Targeted Biopsy Warranted
PI-RADS 1 and 2 lesions are considered very unlikely and unlikely to represent clinically significant prostate cancer, respectively. For PI-RADS 1 (approximately 2% csPCa risk) and PI-RADS 2 (approximately 6% csPCa risk), targeted biopsy is not recommended. However, if the patient has a clinical indication for prostate biopsy based on PSA kinetics or other risk factors, systematic biopsy may still be offered since some clinically significant cancers are MRI-invisible. A negative or low-suspicion MRI reduces but does not eliminate the need for biopsy in all cases.
PI-RADS 3 — Equivocal (Individualized Management)
PI-RADS 3 is the most clinically challenging category. With an approximately 16% csPCa risk, it represents a zone where neither biopsy nor deferral is clearly mandated by the score alone. Management should be individualized based on PSA density, prior biopsy history, patient preference, and clinical risk factors. PSA density below 0.15 ng/mL/mL combined with no prior biopsy and low clinical suspicion generally supports active surveillance with repeat MRI in 12 months. PSA density of 0.15 or higher, a history of prior negative systematic biopsy, or strong family history typically warrants targeted biopsy.
PI-RADS 4 and 5 — Biopsy Recommended
PI-RADS 4 (approximately 35% csPCa risk) and PI-RADS 5 (approximately 60–75% csPCa risk) are considered high and very high suspicion respectively. MRI-targeted biopsy using cognitive, MRI/ultrasound fusion, or in-bore techniques is recommended. The standard approach combines targeted biopsy cores (typically 2–4 per lesion) with concurrent systematic biopsy (12 cores) to maximize detection of both MRI-visible and MRI-invisible cancers. For PI-RADS 5 lesions in patients who are otherwise biopsy-naive, the positive predictive value for csPCa is approximately 60–75%, meaning that approximately 25–40% of PI-RADS 5 lesions will not harbor csPCa on biopsy — a negative biopsy in a PI-RADS 5 patient warrants reassessment and possibly repeat biopsy.
mpMRI Components
T2W (T2-weighted imaging) — Structural anatomy. Key sequence for TZ lesions. Suspicious features: hypointense mass with ill-defined margins, disruption of capsule or seminal vesicle invasion.
DWI (Diffusion-weighted imaging) + ADC map — Dominant sequence for PZ lesions. High-grade tumors show restricted diffusion (low ADC, high signal on high b-value DWI). Most sensitive sequence for clinically significant prostate cancer. The ADC map provides quantitative information; lower ADC values correlate with higher Gleason grade.
DCE (Dynamic Contrast Enhancement) — IV contrast series acquired dynamically. Positive DCE: early or simultaneous focal enhancement compared to adjacent normal tissue, corresponding to the T2W/DWI lesion location. Role is adjunct in v2.1 — used for upgrading PI-RADS 3 PZ lesions to PI-RADS 4 when DWI score is 3 and DCE is positive. Does not affect TZ scoring.
Limitations & Considerations
PI-RADS v2.1 has significant interreader variability, particularly for PI-RADS 3 lesions and for T2W scoring in the transition zone. Studies report reader agreement kappa values of 0.4–0.6 for PI-RADS categories, reflecting moderate agreement. Radiologist experience significantly affects score accuracy — centers performing fewer than 100 prostate MRI studies per year show lower sensitivity for csPCa detection compared to high-volume centers. For high-stakes cases, second-opinion review by an experienced genitourinary radiologist is appropriate.
Technical quality requirements for diagnostic mpMRI are stringent: field strength of 3T is preferred (1.5T with endorectal coil is acceptable), and the DWI sequence requires high b-value images (b ≥ 1400 s/mm²) to maintain sensitivity. Inadequate technical quality — due to patient motion, poor shimming, or insufficient b-value — degrades score accuracy and may necessitate repeat imaging. Not all prostate MRI studies meet diagnostic quality standards, and the radiologist's quality assessment should be documented.
PI-RADS scores have been validated primarily in biopsy-naive patients. Performance in post-treatment settings (post-radiation therapy, post-hormone therapy, or post-focal therapy) differs substantially from the published benchmarks, and score thresholds for biopsy may need adjustment. Additionally, PI-RADS does not account for all imaging features that modify risk: lesion volume, extraprostatic extension, seminal vesicle involvement, and lymph node status are reported separately and significantly affect staging and treatment planning.
References
American College of Radiology. PI-RADS Prostate Imaging – Reporting and Data System, Version 2.1. ACR/ESUR/AdMeTech. 2019. Available at: acr.org/Clinical-Resources/Reporting-and-Data-Systems/PI-RADS
Ahmed HU, El-Shater Bosaily A, Brown LC, et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study. Lancet. 2017;389(10071):815–822. doi:10.1016/S0140-6736(16)32401-1
Kasivisvanathan V, Rannikko AS, Borghi M, et al. (PRECISION Study Group). MRI-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med. 2018;378(19):1767–1777. doi:10.1056/NEJMoa1801993
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging – Reporting and Data System: 2015, Version 2. Eur Urol. 2016;69(1):16–40. doi:10.1016/j.eururo.2015.08.052